☆ 4.7 Article

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients

EUROPEAN JOURNAL OF CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan et al.

Summary: The randomized trial of tebentafusp for metastatic uveal melanoma showed a higher 1-year overall survival rate among patients who received tebentafusp compared to those who received the investigator's choice of therapy, indicating superior efficacy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Prognostic Implications of MRI Melanin Quantification and Cytogenetic Abnormalities in Liver Metastases of Uveal Melanoma

Toulsie Ramtohul et al.

Summary: The study showed that MRI melanin quantification was an independent prognostic factor for overall survival in patients with liver metastases of uveal melanoma (LMUM). Liver metastases with high MRI melanin content and high genetic risk were associated with lower overall survival. The level of pigmentation in M3/8g LMUM identified two subsets that were correlated with distinct clinical outcomes.

CANCERS (2021)

Add to Collection

Article Multidisciplinary Sciences

Pan-cancer analysis of whole genomes

Peter J. Campbell et al.

NATURE (2020)

Add to Collection

Review Medicine, General & Internal

Uveal melanoma

Martine J. Jager et al.

NATURE REVIEWS DISEASE PRIMERS (2020)

Add to Collection

Article Genetics & Heredity

Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab

Peter A. Johansson et al.

IMMUNOGENETICS (2019)

Add to Collection

Article Oncology

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Ernesto Rossi et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

Add to Collection

Article Oncology

Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations

Manuel Rodrigues et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Multidisciplinary Sciences

Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome

Helen R. Davies et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Multidisciplinary Sciences

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors

Manuel Rodrigues et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Hematology

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Mathijs A. Sanders et al.

BLOOD (2018)

Add to Collection

Article Oncology

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

Claire Mignard et al.

JOURNAL OF ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le et al.

SCIENCE (2017)

Add to Collection

Review Oncology

Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review

Markus V. Heppt et al.

CANCER TREATMENT REVIEWS (2017)

Add to Collection

Article Oncology

Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies

Alain P. Algazi et al.

CANCER (2016)

Add to Collection

Review Oncology

Hypermutation in human cancer genomes: footprints and mechanisms

Steven A. Roberts et al.

NATURE REVIEWS CANCER (2014)

Add to Collection

Article Oncology

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

N. Penel et al.

ANNALS OF ONCOLOGY (2013)

Add to Collection

Article Oncology

Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group

S. Cousin et al.

ANNALS OF ONCOLOGY (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.